详细信息
依那普利叶酸片治疗H型高血压的疗效及安全性的Meta分析 被引量:1
The Efficacy and Safety of Enalapril Maleate and Folic Acid Tablets in the Treatment of H-type Hypertension:A Meta Analysis
文献类型:期刊文献
中文题名:依那普利叶酸片治疗H型高血压的疗效及安全性的Meta分析
英文题名:The Efficacy and Safety of Enalapril Maleate and Folic Acid Tablets in the Treatment of H-type Hypertension:A Meta Analysis
作者:赵信科[1,2];蒋虎刚[2];王新强[2];赵晓彬[2];李应东[1,2]
第一作者:赵信科
机构:[1]甘肃中医药大学附属医院,甘肃兰州730020;[2]甘肃中医药大学,甘肃兰州730000
第一机构:甘肃中医药大学第二附属医院
年份:2022
卷号:36
期号:1
起止页码:47
中文期刊名:实用中医内科杂志
外文期刊名:Journal of Practical Traditional Chinese Internal Medicine
基金:甘肃省科技重大专项计划(20ZD7FA002)。
语种:中文
中文关键词:依那普利叶酸片;H型高血压;Meta分析
外文关键词:enalapril maleate and folic acid tablets;H-type hypertension;Meta analysis
摘要:目的基于Meta分析评价依那普利叶酸片治疗H型高血压(HHT)的疗效及安全性。方法检索中国知网(CNKI)、万方(WanFang)、维普(VIP)、PubMed、Cochrane library等数据库建库至2020年11月收录的依那普利叶酸片治疗HHT随机对照试验(RCTs)。本研究依据纳入、排除标准筛选检索获得的文献后最终共纳入45项RCTs,共7744例患者,试验组3872例、对照组3872例。采用RevMan 5.3软件进行Meta分析。结果与对照组相比,试验组对HHT患者的同型半胱氨酸(Hcy)(MD=-4.04,95%CI[-4.9,-3.18],P<0.00001)、收缩压(SBP)(MD=-7.59,95%CI[-9.46,-5.72],P<0.00001)、舒张压(DBP)(MD=-5.85,95%CI[-7.10,-4.6],P<0.00001)、临床总有效率(MD=4.29,95%CI[3.37,5.47],P<0.00001)及心脑血管事件发生率(MD=0.22,95%CI[0.16,0.32],P<0.00001)的改善具有明显优势,差异有统计学意义;安全性方面,与对照组相比,试验组不良反应发生率较低(MD=0.48,95%CI[0.25,0.92],P=0.03),差异有统计学意义。结论与对照组相比,试验组可明显改善HHT患者的Hcy及血压水平并能有效预防远期心脑血管事件的发生,且安全性较好。
Objective To evaluate the efficacy and safety of Enalapril Maleate and Folic Acid Tablets in the treatment of H-type hypertension based on Meta analysis.Methods A search was made for randomized controlled trials(RCTs) of Enalapril Maleate and Folic Acid Tablets in the treatment of H-type hypertension included in the databases of CNKI,Wanfang,VIP PubMed,Cochrane library and other databases included in November 2020.In this study,based on the inclusion and exclusion criteria,a total of 45 RCTs were finally included in the literature after screening and retrieval,with a total of 7744 patients,3872 cases in the experimental group and 3872 cases in the control group.RevMan 5.3 software was used for meta analysis.Results Compared with the control group,the test group had a positive effect on homocysteine(Hcy)(MD=-4.04,95%CI[-4.9,-3.18],P<0.000 01),systolic blood pressure(SBP)(MD=-7.59),95%CI[-9.46,-5.72],P<0.000 01),diastolic blood pressure(DBP)(MD=-5.85,95%CI[-7.10,-4.6],P<0.000 01),total clinical effective rate(MD=4.29,95%CI[3.37,5.47],P<0.000 01) and the incidence of cardiovascular and cerebrovascular events(MD=0.22,95%CI[0.16,0.32],P<0.000 01) and other aspects have obvious advantages,the difference is statistical In terms of safety,compared with the control group,the incidence of adverse reactions in the experimental group was lower(MD=0.48,95%CI[0.25,0.92],P=0.03),and the difference was statistically significant.Conclusion This study found that compared with the control group,the test group can significantly improve the Hcy and blood pressure levels of patients with H-type hypertension and can effectively prevent the occurrence of long-term cardiovascular and cerebrovascular events,and has better safety.
参考文献:
正在载入数据...